Long-term efficacy of endovascular ultrasound renal denervation in resistant hypertension: 6-year results from the ACHIEVE study

Long-term efficacy of endovascular ultrasound renal denervation in resistant hypertension: 6-year results from the ACHIEVE study - ACHIEVE Long-Term Follow-Up Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49583

Enrollment

Registered

2020-12-23

Start date

2021-08-31

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Initial enrolment in the ACHIEVE-study; - Treated with the Paradise ultrasound renal denervation system; - Informed consent; - The patient agrees to follow-up.

Exclusion criteria

Exclusion criteria: Not applicable.

Design outcomes

Primary

Measure	Time frame
Change in 24h ambulatory systolic BP between baseline and 6 years.	—

Secondary

Measure	Time frame
Major Adverse Event (MAE) rate (including any of the following elements within 6 years: mortality, embolic events causing end organ damage, renal failure (eGFR	—

Countries

Netherlands

Outcome results